Evidence map›Paper›PMID 33799431›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.

Murali Kesavan, Danielle Meyrick, Marat Gallyamov, J Harvey Turner, Sharon Yeo, Giuseppe Cardaci, Nat P Lenzo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023
    Guideline
  2. The Prostate · 2022
    Pooled it
  3. Article
  4. On the Way for Patients with Prostate Cancer to the Best Use of PSMA.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Murali KesavanDepartment of Haematology, School of Medicine, The University of Western Australia, Perth 6009, Australia.
Danielle MeyrickDepartment of Nuclear Medicine, School of Medicine, The University of Western Australia, Perth 6009, Australia.
Marat GallyamovGenesisCare, East Fremantle, Fremantle 6158, Australia.
J Harvey TurnerDepartment of Nuclear Medicine, School of Medicine, The University of Western Australia, Perth 6009, Australia.
Sharon YeoGenesisCare, East Fremantle, Fremantle 6158, Australia.
Giuseppe CardaciSchool of Medicine, The University of Notre Dame, Fremantle 6160, Australia.
Nat P LenzoGenesisCare, East Fremantle, Fremantle 6158, Australia.ORCID 0000-0003-4882-8766
Fremantle Hospital · AUThe University of Western Australia · AUThe University of Notre Dame Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (

methodsPatients with mCRPC and adequate bone marrow/liver function were included. All patients included underwent baseline and response assessment by Gallium-68-PSMA-11 positron emission tomography/computed tomography (

resultsOne hundred patients completed one cycle of

conclusion

Indexed as

hematologic toxicityLuPSMAmCRPCMDS

Identifiers

PMID33799431
PMCPMC8001812
OpenAlexW3138714546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.